Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06357806
Status:
RECRUITING
Last Update Posted:
2024-06-12
First Post:
2024-03-20
Brief Title:
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
Sponsor:
Beijing 302 Hospital
Organization:
Beijing 302 Hospital
Study Overview
Official Title:
The Safety and Efficacy of PD-1 Antibody Combined With Pegylated Interferon-α Therapy to Promote the Clinical Cure in Nucleoside Acid Analogues-suppressed Chronic Hepatitis B Patients A Protocol for the Prospective Pilot Study
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective open-labled randomized controlled study to assess efficacy and safety of treatment with Sintilimab PD-1 antibody combined Peg-IFNα-2b in CHB patients on stable NAs treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None